Sigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Sigilon Therapeutics

07/08/2023 19:42

* Sigilon Therapeutics Inc  SGTX.OQ  reported a quarterly
adjusted
loss of $3.00​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of $4.71 per share.
    * Revenue rose 104.6% to $5.90 million from a year ago;
analysts
expected $4.25 million. 
    * Sigilon Therapeutics Inc's reported EPS for the quarter
was a
loss of $3.00​.
    * The mean earnings estimate of analysts had fallen by
about 57.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Sigilon Therapeutics Inc shares had fallen by 4.0% this
quarter and gained 374.9% so far this year.
    * The company reported a quarterly loss of $7.51 million.
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $30.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 7 at 06:42 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -4.71          -3.00          Beat
 Mar. 31 2023      -2.95          -2.99          Missed
 Dec. 31 2022      -4.91          -2.73          Beat
 Sep. 30 2022      -5.52          -3.51          Beat